FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893386720> ?p ?o ?g. }

• W2893386720 endingPage "310" @default.
• W2893386720 startingPage "301" @default.
• W2893386720 abstract "Patients with BRAF V600 ( BRAF ) mutated metastatic melanoma are eligible for therapy with both immune checkpoint inhibitors and targeted therapies, making treatment choice a complex decision. The present study aimed to describe patterns of treatment with immunotherapy and targeted therapy and BRAF testing in patients with metastatic melanoma presumed to have BRAF mutations ( BRAF +) in the years following the approval of the newer generation of immune checkpoint inhibitors and targeted therapies (2014–2016). Two large US commercial claims databases [Truven Health Analytics MarketScan and IQVIA Real-World Data Adjudicated Claims – USA (IQVIA RWD Adjudicated Claims – USA)] were used. Patients were presumed BRAF + if they received at least 2 lines of therapy of which at least 1 included targeted therapy. Sequence of lines of therapy and regimens used in first (1L), second (2L), and third (3L), as well as timing of BRAF testing by sequence of therapy were described. In the Truven sample ( n =162), targeted therapy was used by 66% in 1L and by 54% in 2L, and 62% had a BRAF test; in the IQVIA RWD Adjudicated Claims – USA sample ( n =247), targeted therapy was used by 62% in 1L and by 50% in 2L, and 68% had a BRAF test. Among those with a claim for a BRAF test prior to 1L, over two-thirds were initiated on targeted therapy. These findings suggest that the rate of BRAF testing remained low in the years following the approval of BRAF -targeted regimens for metastatic disease. Given the recently approved adjuvant treatment options for stage III melanoma, improving the rates of BRAF testing becomes increasingly important." @default.
• W2893386720 created "2018-10-05" @default.
• W2893386720 creator A5017834828 @default.
• W2893386720 creator A5026361648 @default.
• W2893386720 creator A5040623452 @default.
• W2893386720 creator A5058741297 @default.
• W2893386720 creator A5063896009 @default.
• W2893386720 creator A5075552871 @default.
• W2893386720 creator A5084512170 @default.
• W2893386720 date "2019-06-01" @default.
• W2893386720 modified "2023-10-16" @default.
• W2893386720 title "Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive" @default.
• W2893386720 cites W1532851266 @default.
• W2893386720 cites W1534815147 @default.
• W2893386720 cites W1543684037 @default.
• W2893386720 cites W1827097565 @default.
• W2893386720 cites W1879616740 @default.
• W2893386720 cites W1965370740 @default.
• W2893386720 cites W2006741643 @default.
• W2893386720 cites W2016895528 @default.
• W2893386720 cites W2020727013 @default.
• W2893386720 cites W2086891934 @default.
• W2893386720 cites W2091100650 @default.
• W2893386720 cites W2096251377 @default.
• W2893386720 cites W2101024529 @default.
• W2893386720 cites W2103220202 @default.
• W2893386720 cites W2114903025 @default.
• W2893386720 cites W2116997650 @default.
• W2893386720 cites W2128542677 @default.
• W2893386720 cites W2128758225 @default.
• W2893386720 cites W2129168200 @default.
• W2893386720 cites W2133075384 @default.
• W2893386720 cites W2135925159 @default.
• W2893386720 cites W2152980179 @default.
• W2893386720 cites W2156078931 @default.
• W2893386720 cites W2160834915 @default.
• W2893386720 cites W2163188200 @default.
• W2893386720 cites W2166262263 @default.
• W2893386720 cites W2166662937 @default.
• W2893386720 cites W2174480090 @default.
• W2893386720 cites W2197956326 @default.
• W2893386720 cites W2254594392 @default.
• W2893386720 cites W2339612083 @default.
• W2893386720 cites W2540613192 @default.
• W2893386720 cites W2560367415 @default.
• W2893386720 cites W2570618306 @default.
• W2893386720 cites W2572174216 @default.
• W2893386720 cites W2603680355 @default.
• W2893386720 cites W2753432434 @default.
• W2893386720 cites W2761314488 @default.
• W2893386720 cites W2770575680 @default.
• W2893386720 cites W2793551437 @default.
• W2893386720 cites W2800623812 @default.
• W2893386720 cites W2804098934 @default.
• W2893386720 cites W28400483 @default.
• W2893386720 cites W4238123838 @default.
• W2893386720 doi "https://doi.org/10.1097/cmr.0000000000000504" @default.
• W2893386720 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6494034" @default.
• W2893386720 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30247203" @default.
• W2893386720 hasPublicationYear "2019" @default.
• W2893386720 type Work @default.
• W2893386720 sameAs 2893386720 @default.
• W2893386720 citedByCount "6" @default.
• W2893386720 countsByYear W28933867202019 @default.
• W2893386720 countsByYear W28933867202022 @default.
• W2893386720 countsByYear W28933867202023 @default.
• W2893386720 crossrefType "journal-article" @default.
• W2893386720 hasAuthorship W2893386720A5017834828 @default.
• W2893386720 hasAuthorship W2893386720A5026361648 @default.
• W2893386720 hasAuthorship W2893386720A5040623452 @default.
• W2893386720 hasAuthorship W2893386720A5058741297 @default.
• W2893386720 hasAuthorship W2893386720A5063896009 @default.
• W2893386720 hasAuthorship W2893386720A5075552871 @default.
• W2893386720 hasAuthorship W2893386720A5084512170 @default.
• W2893386720 hasBestOaLocation W28933867201 @default.
• W2893386720 hasConcept C121608353 @default.
• W2893386720 hasConcept C126322002 @default.
• W2893386720 hasConcept C143998085 @default.
• W2893386720 hasConcept C2776999253 @default.
• W2893386720 hasConcept C2777658100 @default.
• W2893386720 hasConcept C2777701055 @default.
• W2893386720 hasConcept C2777982462 @default.
• W2893386720 hasConcept C2780851360 @default.
• W2893386720 hasConcept C2781230642 @default.
• W2893386720 hasConcept C2994587330 @default.
• W2893386720 hasConcept C502942594 @default.
• W2893386720 hasConcept C71924100 @default.
• W2893386720 hasConceptScore W2893386720C121608353 @default.
• W2893386720 hasConceptScore W2893386720C126322002 @default.
• W2893386720 hasConceptScore W2893386720C143998085 @default.
• W2893386720 hasConceptScore W2893386720C2776999253 @default.
• W2893386720 hasConceptScore W2893386720C2777658100 @default.
• W2893386720 hasConceptScore W2893386720C2777701055 @default.
• W2893386720 hasConceptScore W2893386720C2777982462 @default.
• W2893386720 hasConceptScore W2893386720C2780851360 @default.
• W2893386720 hasConceptScore W2893386720C2781230642 @default.
• W2893386720 hasConceptScore W2893386720C2994587330 @default.
• W2893386720 hasConceptScore W2893386720C502942594 @default.

• next